Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Biour, R. Poupon, J-D Grangé, O. Chazouilleres.
Hépatotoxicité des médicaments. 13emise á jour du fichier bibliographique des atteintes hépatiques et des médicaments reponsables.
Gastroenterol Clin Biol, 24 (2000), pp. 1052-1091
[2.]
H.J. Zimmmerman.
Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver.
[3.]
J. Bernuau, B. Rueff.
Benhamou J-P. Fulminant and subfulminant liver failure: definitions and causes.
Semin Liver Dis, 6 (1986), pp. 97-106
[4.]
Y. Tameda, M. Hamada, K. Takase, T. Nakano, Y. Kosaka.
Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative).
Hepatology, 23 (1996), pp. 465-470
[5.]
O.M. Bakke, M. Manocchia, F. De Abajo, K.I. Kaitin, L. Lasagna.
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.
Clin Pharmacol Ther, 58 (1995), pp. 108-117
[6.]
F. Ballet.
Hepatotoxicity in drug development: detection, significance and solutions.
J Hepatol, 26 (1997), pp. 26-36
[8.]
R.J. Andrade, M.I. Lucena, R. Martín-Vivaldi, M.C. Fernández, F. Nogueras, G. Peláez, et al.
Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist.
J Hepatol, 31 (1999), pp. 641-646
[9.]
Nuevas perspectivas de la farmacovigilancia en España y en la Unión Europea,
[10.]
Informe anual.
Notificación voluntaria de reacciones adversas a medicamentos. Tarjeta amarilla. Divisió de Farmacología Clínica. Institut Catalá de Farmacología.
Universitat Autónoma de Barcelona, abril, (1984),
[11.]
J-R Laporte, D. Capellá.
El sistema español de farmacovigilancia.
Med Clin (Barc), 103 (1994), pp. 335-336
[12.]
M. Madurga, F.J. De Abajo, G. Martín-Serrano, D. Montero.
El sistema español de farmacovigilancia.
Nuevas perspectivas de la farmacovigilancia en España y en la Unión Europea, pp. 37-61
[13.]
F.J. De Abajo, M. Madurga, J.F. Olalla, R. Palop.
La farmacovigilancia en España.
Madrid: Instituto de Salud Carlos III, (1992),
[14.]
A. Carvajal.
Farmacoepidemiología. Secretariado de Publicaciones. Universidad de Valladolid.
Valladolid, (1994),
[15.]
A. Álvarez-Requejo, A. Carvajal, B. Bégaud, Y. Moride, T. Vega, L.H. Arias, et al.
Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system.
Eur J Clin Pharmacol, 54 (1998), pp. 483-488
[16.]
R.J. Andrade, M.I. Lucena, R. Alcántara, J.M. Fraile.
Bentazepamassociated chronic liver disease.
Lancet, 343 (1994), pp. 860
[17.]
R.J. Andrade, M.I. Lucena, M. Rodríguez-Mendizabal.
Hepatic injury caused by acarbose.
Ann Intern Med, 124 (1996), pp. 931
[18.]
F. Assal, L. Spahr, A. Hadengue, L. Rubbia-Brandt, P.R. Burkhard, L. Rubbici-Bandt.
Tolcapone and fulminant hepatitis.
Lancet, 352 (1998), pp. 958
[19.]
S. Erill.
La carta al director.
Med Clin (Barc), 109 (1997), pp. 513-514
[20.]
L.A. García-Rodríguez, S. Pérez-Gutthann.
Use of UK General Practice Research Database for pharmacoepidemiology.
Br J Clin Pharmacol, 45 (1998), pp. 419-425
[21.]
H. Jick, S.S. Jick, L. Derby.
Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.
Br Med J, 302 (1991), pp. 766-768
[22.]
L.A. García-Rodríguez, M-A Wallander, B.H. Stricker.
The risk of acute liver injury associated with cimetidine and other acidsuppressing anti-ulcer drugs.
Br J Clin Pharmacol, 43 (1997), pp. 183-188
[23.]
L.A. García-Rodríguez, S. Pérez-Gutthan, A.M. Walker, L. Lueck.
The role of nonsteroidal anti-inflammatory drugs in acute liver injury.
Br Med J, 305 (1992), pp. 1865-1868
[24.]
S. Perez-Guttham, L.A. García-Rodríguez.
The increased risk of hospitalization fo acute liver injury in a population with exposure to multiples drugs.
Epidemiology, 4 (1993), pp. 496-501
[25.]
J.L. Carson, A. Duff, B.L. Strom.
Drug-induced acute liver disease.
Pharmacoepidemiol Drug Safety, 2 (1993), pp. S19-S23
[26.]
H. Jick, A.M. Walker, J. Porter.
Drug-induced liver disease.
J Clin Pharmacol, 21 (1981), pp. 359-364
[27.]
R.J. Andrade, M.I. Lucena, J.M. Pérez-Moreno, M.C. Fernández, R. Martín-Vivaldi, M. Ramos-Lora, et al.
Proyecto de reacciones adversas hepatotóxicas en Andalucía: resultados preliminares.
Rev And Patol Digest, 21 (1998), pp. 70-76
[28.]
G.P. Aithal, M.D. Rawlins, C.P. Day.
Accuracy of hepatic adverse drug reactions in one English health region.
Br Med J, 319 (1999), pp. 1541
[29.]
R.J. Andrade, M.I. Lucena, M.D. García-Escaño, R. Camargo.
Severe idiosyncratic acute hepatic injury caused by paracetamol.
J Hepatol, 28 (1998), pp. 1078
[30.]
M.I. Lucena, R.J. Andrade, L. Rodrigo, J. Salmerón, A. Álvarez, M.A. López-Garrido, et al.
Trovafloxacin-induced acute hepatitis.
Clin Infect Dis, 30 (2000), pp. 400-401
[31.]
García-Cortés M, Andrade RJ, Lucena MI, Sánchez-Martínez H, Fernández MC, Ferrer T et al. Hepatotoxicidad por flutamida: análisis de una serie y revisión de la literatura. Rev Esp Enferm Digest 2001. En prensa.
[32.]
R.J. Andrade, M.I. Lucena, M.C. Fernández-Sánchez, G. Peláez.
Hepatotoxicidad por paracetamol a dosis terapéuticas.
Med Clin (Barc), 109 (1997), pp. 317-318
[33.]
R.J. Andrade, M.I. Lucena, F. Melgarejo, MD. García-Escaño.
¿Hepatotoxicidad por isoniacida o por paracetamol?.
Gastroenterol Hepatol, 21 (1998), pp. 314-315
[34.]
C. Bénichou.
Criteria for drug-induced liver disorders. Report of an International Consensus Meeting.
J Hepatol, 11 (1990), pp. 272-276
[35.]
G. Danan, C. Bénichou.
Causality assessment of adverse drug reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.
J Clin Epidemiol, 46 (1993), pp. 1323-1330
[36.]
V.A.J. Maria.
Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis.
Hepatology, 26 (1997), pp. 664-669
[37.]
M.I. Lucena, R. Camargo, R.J. Andrade, C. Perez-Sánchez, F. Sánchez de la Cuesta.
Comparison of two clinical scales for causality assessment in hepatotoxicity.
Hepatology, 33 (2001), pp. 123-130
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
